Cell type-associated traits map for the [Madissoon_2020_spleen_B naive][link to cell ontology]. Due to the large number of UKBB panel traits, this figure shows the non-UKBB traits with a CSEA p (chi2) < 1e-04 as default, and users can change it to 1e-03, 1e-05, or 1e-06. For each cell type and trait association pair (shown as an edge in the figure), there may be multiple TAG sets, each defined at a different threshold. The pair with the minimum p-value is shown in the figure, with the p-value showing along each edge. The number of edges in the figure is thus less than (or equal to) the number of entries in the table below.” The association association is listed in the table at bottom, Because each trait might have multiple TAG sets defined at different thresholds, multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns).
Table. List of Cell type-associated traits pairs for [Madissoon_2020_spleen_B naive]. If the network above is too complicated. the users could obtain the association information from the table at bottom. Because each trait has multiple TAG sets defined at different thresholds, there may be multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns). Users could identify the most significant association by sorting “CSAE p (chi2)” column.
Trait Name | Trait Full Name | Panel | Author | Year | Cases* | Controls | TAG Set Threshold |
CSEA p (chi2) |
---|---|---|---|---|---|---|---|---|
ADHD | Attention Deficit Hyperactivity Disorder | ETC | Demontis | 2017 | 19099 | 34194 | 5.00e-2 | 2.83e-3 |
Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 5.00e-2 | 2.17e-3 |
Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-2 | 7.50e-3 |
Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-3 | 7.23e-4 |
Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-4 | 8.69e-5 |
Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-5 | 1.67e-3 |
Alzheimers | Alzheimer's Disease | MTC | Jansen | 2019 | 71880 | 383378 | 1.00e-3 | 4.27e-2 |
Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 5.00e-2 | 4.72e-2 |
Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 1.00e-4 | 4.66e-2 |
Anorexia Nervosa | Anorexia Nervosa | MTC | Boraska | 2014 | 2907 | 14860 | 5.00e-2 | 4.30e-2 |
Anorexia Nervosa | Anorexia Nervosa | MTC | Duncan | 2017 | 3495 | 10982 | 5.00e-2 | 1.25e-2 |
Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 5.00e-2 | 7.98e-4 |
Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-2 | 1.57e-3 |
Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-3 | 3.94e-3 |
Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-4 | 7.37e-3 |
Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-5 | 4.52e-3 |
Asthma | Asthma | MTC | Moffatt | 2010 | 10365 | 16110 | 1.00e-3 | 4.62e-2 |
Bone Mineral Density | Bone Mineral Density | MTC | Styrkarsdottir | 2008 | 4657 | 207514 | 5.00e-2 | 3.29e-3 |
Bone Mineral Density | Bone Mineral Density | MTC | Styrkarsdottir | 2008 | 4657 | 207514 | 1.00e-2 | 4.39e-2 |
Cerebral White Matter Hyperintensity | Cerebral White Matter Hyperintensity | MTC | Traylor | 2016 | NA | 3670 | 5.00e-2 | 3.50e-2 |
Clozapine Induced Agranulocytosis | Clozapine Induced Agranulocytosis | ETC | Goldstein | 2014 | 161 | 1196 | 5.00e-2 | 1.54e-2 |
Cognitive Performance | Cognitive Performance | MTC | Rietveld | 2014 | NA | 106736 | 1.00e-2 | 1.32e-2 |
CAD | Coronary Artery Disease | MTC | Nelson | 2017 | 18467 | 45264 | 1.00e-2 | 4.53e-2 |
CAD | Coronary Artery Disease | MTC | Schunkert | 2011 | 22233 | 64762 | 1.00e-3 | 3.11e-2 |
CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 5.00e-2 | 4.38e-4 |
CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-2 | 3.38e-4 |
CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-3 | 5.28e-3 |
CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-4 | 9.53e-5 |
CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-5 | 4.70e-4 |
Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 5.00e-2 | 5.83e-3 |
Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 1.00e-2 | 1.37e-2 |
Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 1.00e-4 | 1.51e-2 |
Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 1.00e-5 | 1.05e-2 |
Extraversion | Extraversion | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-2 | 2.94e-2 |
Extraversion | Extraversion | MTC | van-den-Berg | 2016 | NA | 63030 | 1.00e-2 | 2.94e-2 |
Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 5.00e-2 | 1.74e-2 |
Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 1.00e-2 | 2.97e-4 |
Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 1.00e-3 | 3.05e-3 |
Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 1.00e-4 | 4.63e-2 |
Intelligence | Intelligence | MTC | Sniekers | 2017 | NA | 78308 | 5.00e-2 | 1.46e-2 |
Intelligence | Intelligence | MTC | Sniekers | 2017 | NA | 78308 | 1.00e-2 | 5.29e-3 |
Intelligence | Intelligence | MTC | Sniekers | 2017 | NA | 78308 | 1.00e-3 | 1.12e-3 |
Intelligence | Intelligence | MTC | Sniekers | 2017 | NA | 78308 | 1.00e-4 | 2.43e-2 |
Male Pattern Baldness | Male Pattern Baldness | MTC | Hagenaars | 2017 | NA | 52874 | 5.00e-2 | 1.61e-3 |
Male Pattern Baldness | Male Pattern Baldness | MTC | Hagenaars | 2017 | NA | 52874 | 1.00e-2 | 2.09e-2 |
Male Pattern Baldness | Male Pattern Baldness | MTC | Hagenaars | 2017 | NA | 52874 | 1.00e-4 | 2.72e-2 |
Male Pattern Baldness | Male Pattern Baldness | MTC | Hagenaars | 2017 | NA | 52874 | 1.00e-5 | 2.80e-2 |
MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-3 | 5.32e-3 |
MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-4 | 7.56e-4 |
MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-5 | 4.09e-4 |
Neuroticism | Neuroticism | MTC | Luciano | 2017 | NA | 329821 | 1.00e-2 | 1.21e-2 |
Neuroticism | Neuroticism | MTC | Luciano | 2017 | NA | 329821 | 1.00e-3 | 3.37e-3 |
Neuroticism | Neuroticism | MTC | Luciano | 2017 | NA | 329821 | 1.00e-4 | 3.77e-3 |
Neuroticism | Neuroticism | MTC | Luciano | 2017 | NA | 329821 | 1.00e-5 | 4.08e-2 |
Obesity Childhood | Obesity Childhood | MTC | Bradfield | 2012 | 5530 | 8318 | 1.00e-4 | 3.23e-2 |
Offspring Birth Weight | Offspring Birth Weight | MTC | Beaumont | 2018 | NA | 68258 | 5.00e-2 | 1.54e-2 |
Offspring Birth Weight | Offspring Birth Weight | MTC | Beaumont | 2018 | NA | 68258 | 1.00e-2 | 1.00e-2 |
Offspring Birth Weight | Offspring Birth Weight | MTC | Beaumont | 2018 | NA | 68258 | 1.00e-3 | 4.36e-2 |
Parkinsons | Parkinson's Disease | MTC | Pankratz | 2012 | 4238 | 4239 | 5.00e-2 | 1.81e-3 |
Parkinsons | Parkinson's Disease | MTC | Pankratz | 2012 | 4238 | 4239 | 1.00e-2 | 2.00e-3 |
Partial Epilepsy | Partial Epilepsy | MTC | Kasperaviciute | 2010 | 3445 | 6935 | 5.00e-2 | 3.42e-2 |
Partial Epilepsy | Partial Epilepsy | MTC | Kasperaviciute | 2010 | 3445 | 6935 | 1.00e-2 | 1.01e-2 |
Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 5.00e-2 | 2.52e-2 |
Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-2 | 1.33e-3 |
Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-3 | 1.51e-4 |
Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-4 | 3.13e-4 |
Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-5 | 2.72e-3 |
Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-5 | 4.40e-2 |
Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 5.00e-2 | 5.92e-5 |
Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-2 | 3.99e-4 |
Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-3 | 2.49e-4 |
Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-4 | 2.69e-3 |
Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-5 | 1.10e-3 |
Self Rated Health | Self Rated Health | MTC | Harris | 2016 | NA | 111749 | 1.00e-2 | 2.59e-2 |
Self Rated Health | Self Rated Health | MTC | Harris | 2016 | NA | 111749 | 1.00e-4 | 3.60e-2 |
Self Rated Health | Self Rated Health | MTC | Harris | 2016 | NA | 111749 | 1.00e-5 | 3.17e-2 |
Tetralogy Of Fallot | Tetralogy Of Fallot | MTC | Cordell | 2013 | 835 | 5159 | 1.00e-3 | 2.57e-3 |
Type 2 Diabetes | Type 2 Diabetes | ETC | Morris | 2012 | 12171 | 56862 | 1.00e-2 | 3.17e-2 |
Type 2 Diabetes | Type 2 Diabetes | ETC | Morris | 2012 | 12171 | 56862 | 1.00e-3 | 3.01e-2 |
UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-3 | 4.59e-2 |
UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-4 | 1.09e-2 |
UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-5 | 2.02e-2 |
Vitamin D | Vitamin D | MTC | Manousaki | 2017 | NA | 42274 | 1.00e-2 | 4.61e-2 |
Vitamin D | Vitamin D | MTC | Manousaki | 2017 | NA | 42274 | 1.00e-4 | 3.46e-2 |
Vitamin D | Vitamin D | MTC | Manousaki | 2017 | NA | 42274 | 1.00e-5 | 2.58e-2 |
Waist Hip Ratio Adjusted For BMI | Waist Hip Ratio Adjusted For BMI | MTC | Heid | 2010 | NA | 77167 | 5.00e-2 | 3.25e-2 |
Waist Hip Ratio Adjusted For BMI | Waist Hip Ratio Adjusted For BMI | MTC | Heid | 2010 | NA | 77167 | 1.00e-4 | 2.30e-2 |
Waist Hip Ratio Adjusted For BMI | Waist Hip Ratio Adjusted For BMI | MTC | Heid | 2010 | NA | 77167 | 1.00e-5 | 3.41e-2 |
Albuminuria | Urinary Albumin to Creatinine Ratio | MTC | Teumer | 2016 | NA | 54450 | 1.00e-2 | 1.13e-2 |
Alcohol Consumption | Alcohol Consumption Women Continuous | MTC | Schumann | 2016 | NA | 42900 | 5.00e-2 | 1.94e-2 |
Alcohol Consumption | Alcohol Consumption Women Continuous | MTC | Schumann | 2016 | NA | 42900 | 1.00e-2 | 4.96e-2 |
Alcohol Consumption | Alcohol Consumption Women Continuous | MTC | Schumann | 2016 | NA | 42900 | 1.00e-3 | 2.30e-2 |
Anthropometrics Sex Stratified | Body Mass Index Men | MTC | Randall | 2013 | 60586 | 60856 | 1.00e-4 | 3.16e-2 |
Anthropometrics Sex Stratified | Hip Circumference Adjusted For BMI Women | MTC | Randall | 2013 | NA | 43316 | 5.00e-2 | 1.35e-2 |
Anthropometrics Sex Stratified | Hip Circumference Women | MTC | Randall | 2013 | NA | 43316 | 5.00e-2 | 5.91e-3 |
Anthropometrics Sex Stratified | Hip Circumference Women | MTC | Randall | 2013 | NA | 43316 | 1.00e-2 | 2.46e-2 |
Anthropometrics Sex Stratified | Waist Hip Ratio Adjusted For BMI Men | MTC | Randall | 2013 | NA | 34629 | 5.00e-2 | 1.14e-2 |
Anthropometrics Sex Stratified | Waist Hip Ratio Adjusted For BMI Women | MTC | Randall | 2013 | NA | 42969 | 1.00e-3 | 3.05e-3 |
Anthropometrics Sex Stratified | Waist Hip Ratio Adjusted For BMI Women | MTC | Randall | 2013 | NA | 42969 | 1.00e-4 | 1.56e-2 |
Anthropometrics Sex Stratified | Waist Hip Ratio Men | MTC | Randall | 2013 | NA | 34629 | 5.00e-2 | 7.25e-3 |
Anthropometrics Sex Stratified | Waist Hip Ratio Women | MTC | Randall | 2013 | NA | 42969 | 1.00e-3 | 1.54e-2 |
Anthropometrics Sex Stratified | Weight Women | MTC | Randall | 2013 | NA | 73137 | 1.00e-2 | 4.20e-2 |
Anxiety | Anxiety Continuous | ETC | Otowa | 2016 | NA | 18186 | 5.00e-2 | 5.71e-3 |
Birth Weight | Birth Weight European | ETC | Horikoshi | 2016 | NA | 133903 | 1.00e-3 | 2.76e-2 |
Blood Cells | Hematocrit | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 4.67e-3 |
Blood Cells | Mean Erythrocyte Cell Volume | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 1.43e-2 |
Blood Cells | Neutrophil Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 5.84e-3 |
Blood Cells | Neutrophil Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 5.63e-3 |
Blood Cells | Total Blood Hemoglobin | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 2.40e-3 |
Blood Cells | Total Blood Hemoglobin | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 4.10e-2 |
Blood Cells | White Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 6.67e-3 |
Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 5.00e-2 | 5.43e-3 |
Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 1.00e-2 | 2.59e-3 |
Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 1.00e-3 | 1.15e-2 |
Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 1.00e-4 | 4.45e-2 |
Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 1.00e-2 | 2.20e-3 |
Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 1.00e-3 | 7.26e-3 |
Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 5.00e-2 | 1.15e-3 |
Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-2 | 4.03e-3 |
Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-3 | 1.05e-4 |
Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-4 | 1.74e-2 |
Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 5.00e-2 | 1.21e-2 |
Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-2 | 3.27e-4 |
Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-3 | 4.91e-3 |
BMI Age Stratified | BMI Men Age Over 50 | MTC | Winkler | 2015 | NA | 90988 | 5.00e-2 | 1.62e-3 |
BMI Physical Activity Interaction | BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 3.60e-2 |
BMI Physical Activity Interaction | BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 4.69e-2 |
BMI Physical Activity Interaction | BMI Inactive European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 5.90e-3 |
BMI Physical Activity Interaction | BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 1.82e-2 |
BMI Physical Activity Interaction | BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 4.41e-2 |
BMI Physical Activity Interaction | BMI Inactive European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 3.87e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 4.44e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 4.58e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 1.61e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 4.72e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 4.40e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 4.86e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 3.71e-3 |
BMI Smoking Adjusted | BMI Smoking Adjusted Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 4.59e-2 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 2.69e-2 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 3.38e-2 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 1.42e-2 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 5.22e-3 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-4 | 2.32e-2 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-5 | 4.96e-2 |
Cognitive Functions | College | MTC | Davies | 2016 | NA | 111114 | 5.00e-2 | 1.76e-2 |
Cognitive Functions | College | MTC | Davies | 2016 | NA | 111114 | 1.00e-3 | 5.44e-3 |
Cognitive Functions | College | MTC | Davies | 2016 | NA | 111114 | 1.00e-4 | 1.53e-3 |
Cognitive Functions | College | MTC | Davies | 2016 | NA | 111114 | 1.00e-5 | 3.27e-2 |
Cognitive Functions | Verbal Numeric Reasoning | MTC | Davies | 2016 | NA | 36035 | 5.00e-2 | 1.19e-2 |
Coronary Artery Disease | Coronary Artery Disease Recessive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 5.00e-2 | 2.53e-2 |
Coronary Artery Disease | Coronary Artery Disease Recessive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 1.00e-3 | 4.37e-2 |
Coronary Artery Disease | Myocardial Infarction Additive Model | MTC | Nikpay | 2015 | 27509 | 99121 | 1.00e-5 | 3.58e-2 |
Diarrhoeal Disease | Diarrhea Doctor Diagnosed Age 1 | MTC | Bustamante | 2016 | 1339 | 5064 | 5.00e-2 | 4.77e-2 |
Diarrhoeal Disease | Diarrhea Doctor Diagnosed Age 1 | MTC | Bustamante | 2016 | 1339 | 5064 | 1.00e-2 | 3.18e-2 |
Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight All | MTC | Chu | 2017 | NA | 7324 | 5.00e-2 | 8.85e-3 |
Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight Men | MTC | Chu | 2017 | NA | 3640 | 5.00e-2 | 1.12e-3 |
Ectopic Fat Traits | Pericardial Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 7324 | 5.00e-2 | 2.30e-2 |
Ectopic Fat Traits | Pericardial Adipose Tissue Volume Men | MTC | Chu | 2017 | NA | 3640 | 5.00e-2 | 1.33e-3 |
Ectopic Fat Traits | Pericardial Adipose Tissue Volume Men | MTC | Chu | 2017 | NA | 3640 | 1.00e-3 | 3.97e-2 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14668 | 5.00e-2 | 2.80e-4 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14668 | 1.00e-2 | 5.63e-3 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Men | MTC | Chu | 2017 | NA | 7050 | 5.00e-2 | 1.44e-3 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Men | MTC | Chu | 2017 | NA | 7050 | 1.00e-2 | 2.43e-2 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7618 | 5.00e-2 | 4.23e-3 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7618 | 1.00e-2 | 1.46e-2 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14668 | 5.00e-2 | 1.32e-2 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14668 | 1.00e-2 | 6.58e-4 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Men | MTC | Chu | 2017 | NA | 7050 | 5.00e-2 | 2.78e-3 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Men | MTC | Chu | 2017 | NA | 7050 | 1.00e-2 | 3.66e-2 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7618 | 5.00e-2 | 3.29e-3 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14780 | 5.00e-2 | 2.00e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Attenutation Women | MTC | Chu | 2017 | NA | 5729 | 5.00e-2 | 4.31e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14863 | 5.00e-2 | 8.18e-3 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14863 | 1.00e-2 | 9.18e-3 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14863 | 1.00e-3 | 2.96e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7431 | 5.00e-2 | 2.21e-3 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7431 | 1.00e-3 | 1.17e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14863 | 5.00e-2 | 2.50e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14863 | 1.00e-2 | 2.65e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14863 | 1.00e-3 | 3.46e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7431 | 5.00e-2 | 1.51e-2 |
Educational Attainment | Education Years All | ETC | Okbay | 2016 | NA | 293723 | 1.00e-2 | 1.11e-2 |
Educational Attainment | Education Years All | ETC | Okbay | 2016 | NA | 293723 | 1.00e-3 | 8.92e-3 |
Educational Attainment | Education Years All | ETC | Okbay | 2016 | NA | 293723 | 1.00e-4 | 1.64e-3 |
Educational Attainment | Education Years All | ETC | Okbay | 2016 | NA | 293723 | 1.00e-5 | 4.20e-4 |
Educational Attainment | Education Years Men | MTC | Okbay | 2016 | 0 | 293723 men and women | 5.00e-2 | 5.99e-3 |
Educational Attainment | Education Years Men | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-2 | 7.33e-3 |
Educational Attainment | Education Years Men | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-3 | 5.33e-3 |
Educational Attainment | Education Years Men | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-4 | 2.92e-4 |
Educational Attainment | Education Years Men | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-5 | 7.36e-4 |
Educational Attainment | Education Years Women | MTC | Okbay | 2016 | 0 | 293723 men and women | 5.00e-2 | 4.57e-2 |
Educational Attainment | Education Years Women | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-2 | 1.64e-2 |
Educational Attainment | Education Years Women | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-3 | 5.86e-3 |
Educational Attainment | Education Years Women | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-4 | 9.95e-4 |
Educational Attainment | Education Years Women | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-5 | 1.79e-2 |
Estimated Glomerular Filtration Rate | Chronic Kidney Disease With Diabetes | MTC | Pattaro | 2016 | NA | 11522 | 1.00e-3 | 3.87e-2 |
Estimated Glomerular Filtration Rate | Chronic Kidney Disease Without Diabetes | MTC | Pattaro | 2016 | NA | 118448 | 5.00e-2 | 7.27e-3 |
Estimated Glomerular Filtration Rate | Chronic Kidney Disease Without Diabetes | MTC | Pattaro | 2016 | NA | 118448 | 1.00e-2 | 3.95e-2 |
Estimated Glomerular Filtration Rate | Serum Creatinine | MTC | Pattaro | 2016 | NA | 133413 | 5.00e-2 | 4.89e-3 |
Estimated Glomerular Filtration Rate | Serum Creatinine | MTC | Pattaro | 2016 | NA | 133413 | 1.00e-2 | 2.47e-2 |
Facial Shape | Mod1 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 6.45e-5 |
Facial Shape | Mod16 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 1.56e-2 |
Facial Shape | Mod19 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 9.56e-3 |
Facial Shape | Mod30 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.67e-2 |
Facial Shape | Mod30 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.51e-2 |
Facial Shape | Mod33 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.97e-2 |
Facial Shape | Mod33 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.50e-2 |
Facial Shape | Mod33 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 1.55e-2 |
Facial Shape | Mod34 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 6.77e-3 |
Facial Shape | Mod35 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.15e-2 |
Facial Shape | Mod37 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.03e-2 |
Facial Shape | Mod38 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.46e-2 |
Facial Shape | Mod39 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 5.71e-3 |
Facial Shape | Mod44 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 2.38e-2 |
Facial Shape | Mod45 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.54e-2 |
Facial Shape | Mod60 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.22e-3 |
Facial Shape | Mod61 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.25e-2 |
Facial Shape | Mod63 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.13e-2 |
Facial Shape | Mod7 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.84e-3 |
Facial Shape | Mod9 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.26e-2 |
Gestational Weight Gain | Early Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 8559 | 5.00e-2 | 2.50e-3 |
Gestational Weight Gain | Early Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 8559 | 1.00e-2 | 7.78e-3 |
Gestational Weight Gain | Early Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 8559 | 1.00e-3 | 4.37e-2 |
Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 5.00e-2 | 1.02e-4 |
Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 1.00e-2 | 2.86e-5 |
Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 1.00e-3 | 1.94e-3 |
Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 1.00e-4 | 1.34e-2 |
Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 1.00e-5 | 3.19e-2 |
Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 5.00e-2 | 2.47e-4 |
Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-2 | 3.48e-3 |
Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-4 | 2.94e-2 |
Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-5 | 8.74e-3 |
Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 5.00e-2 | 2.94e-2 |
Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-5 | 1.65e-2 |
Insulin Sensitivity Index | Model 2 | MTC | Walford | 2016 | NA | 16753 | 1.00e-2 | 2.07e-2 |
Insulin Sensitivity Index | Model 3 | MTC | Walford | 2016 | NA | 16753 | 5.00e-2 | 2.04e-2 |
Intracerebral Hemorrhage | All ICH | MTC | Woo | 2014 | 1545 | 1481 | 5.00e-2 | 1.61e-2 |
Ischaemic Stroke | Cardioembolic Stroke | MTC | Traylor | 2012 | 1715 | 12285 | 5.00e-2 | 3.64e-3 |
Kidney Function | CKDi25 | MTC | Gorski | 2015 | NA | 45530 | 5.00e-2 | 4.15e-2 |
Kidney Function | eGFR Decline | MTC | Gorski | 2015 | NA | 45530 | 5.00e-2 | 2.74e-2 |
Kidney Function | eGFR Decline Without Chronic Kidney Disease | MTC | Gorski | 2015 | NA | 45530 | 5.00e-2 | 3.33e-2 |
Kidney Function | Rapid Decline | MTC | Gorski | 2015 | NA | 45530 | 5.00e-2 | 2.96e-2 |
Kidney Function | Rapid Decline Without Chronic Kidney Disease | MTC | Gorski | 2015 | NA | 45530 | 5.00e-2 | 1.87e-2 |
Kidney Function | Serum Cystatine | MTC | Gorski | 2017 | NA | 45530 | 1.00e-3 | 4.96e-2 |
Kidney Function | Serum Cystatin | MTC | Kottgen | 2010 | NA | 67093 | 5.00e-2 | 1.38e-2 |
Leptin | Leptin Adjusted For BMI | MTC | Kilpelainen | 2016 | NA | 32161 | 1.00e-3 | 2.62e-2 |
Leptin | Leptin Not Adjusted For BMI | ETC | Kilpelainen | 2016 | NA | 32161 | 5.00e-2 | 2.36e-2 |
Lipoprotein Associated Phospholipase A2 | Lipoprotein Associated Phospholipase A2 (LpPLA2) Mass | MTC | Suchindran | 2010 | NA | 6668 | 1.00e-2 | 3.72e-3 |
Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 1.18e-2 |
Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 1.48e-3 |
Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-4 | 1.02e-2 |
Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 5.84e-3 |
Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 5.98e-5 |
Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 3.66e-3 |
Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-4 | 5.82e-3 |
TBLH BMD | Total body less head bone mineral density | MTC | Medina-Gomez | 2017 | NA | 10414 | 1.00e-2 | 4.94e-2 |
TBLH BMD | Total body less head bone mineral density | MTC | Medina-Gomez | 2017 | NA | 10414 | 1.00e-3 | 2.91e-2 |
Personality Big5 | Agreeableness | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 2.71e-2 |
Pubertal Anthropometrics | Total Pubertal Height Increase Females | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-3 | 8.39e-3 |
Reproductive Behavior | Age First Birth Female | MTC | Barban | 2016 | NA | 189656 | 1.00e-5 | 4.37e-2 |
Reproductive Behavior | Age First Birth Pooled | ETC | Barban | 2016 | NA | 238064 | 1.00e-4 | 2.43e-2 |
Reproductive Behavior | Number Children Ever Born Female | MTC | Barban | 2016 | NA | 225230 | 5.00e-2 | 7.55e-3 |
Reproductive Behavior | Number Children Ever Born Female | MTC | Barban | 2016 | NA | 225230 | 1.00e-2 | 4.19e-2 |
Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 5.00e-2 | 2.88e-7 |
Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-2 | 2.35e-4 |
Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-3 | 1.36e-4 |
Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-4 | 8.78e-5 |
Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-5 | 1.73e-4 |
Sleep Duration | Oversleeper | MTC | Jones | 2016 | NA | 91306 | 5.00e-2 | 4.08e-4 |
Sleep Duration | Oversleeper | MTC | Jones | 2016 | NA | 91306 | 1.00e-2 | 5.57e-3 |
Sleep Duration | Average Sleep Duration | MTC | Jones | 2016 | NA | 127573 | 5.00e-2 | 6.14e-3 |
Circadian Rhythm | Sleep Chronotype | MTC | Jones | 2016 | NA | 127898 | 5.00e-2 | 2.25e-2 |
Stroke (ischemic) | All Ischemic Stroke | MTC | Traylor | 2017 | 12389 | 62004 | 1.00e-2 | 1.02e-2 |
Social Deprivation | Household Income | MTC | Hill | 2016 | NA | 112005 | 5.00e-2 | 1.49e-2 |
Social Deprivation | Household Income | MTC | Hill | 2016 | NA | 112005 | 1.00e-2 | 4.06e-2 |
Social Deprivation | Household Income One Person Per Household | MTC | Hill | 2016 | NA | 112005 | 5.00e-2 | 5.76e-3 |
Social Deprivation | Household Income One Person Per Household | MTC | Hill | 2016 | NA | 112005 | 1.00e-3 | 7.08e-3 |
Social Deprivation | Townsend Score | MTC | Hill | 2016 | NA | 96900 | 5.00e-2 | 2.30e-2 |
Waist Format 1 | Hip Circumference Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-2 | 4.16e-2 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-5 | 2.91e-2 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-3 | 2.10e-2 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 5.00e-2 | 1.40e-2 |
Waist Format 2 | Hip Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 5.00e-2 | 1.45e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 5.00e-2 | 2.78e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-2 | 2.27e-2 |
Waist Format 2 | Waist Hip Ratio Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-2 | 2.90e-2 |
Waist Format 2 | Waist Hip Ratio Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-3 | 2.97e-2 |
Waist Format 2 | Waist Hip Ratio Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-4 | 9.50e-3 |
SCZ | Schizophrenia | ETC | Ripke | 2014 | 32405 | 42221+í | 1.00e-2 | 3.84e-3 |
SCZ | Schizophrenia | ETC | Ripke | 2014 | 32405 | 42221+í | 1.00e-3 | 4.80e-4 |
SCZ | Schizophrenia | ETC | Ripke | 2014 | 32405 | 42221+í | 1.00e-4 | 1.22e-3 |
SCZ | Schizophrenia | ETC | Ripke | 2014 | 32405 | 42221+í | 1.00e-5 | 9.75e-3 |
T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 5.00e-2 | 5.31e-7 |
T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-2 | 2.35e-4 |
T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-3 | 3.75e-4 |
T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-4 | 6.99e-5 |
T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-5 | 2.60e-5 |
PAN | Pancreatic Cancer | ETC | Amundadottir | 2009 | 1771 | 1805 | 5.00e-2 | 7.76e-3 |
COL | SSGAC_College | ETC | Rietveld | 2013 | NA | 101069 | 1.00e-3 | 3.79e-2 |
COL | SSGAC_College | ETC | Rietveld | 2013 | NA | 101069 | 1.00e-4 | 1.67e-3 |
COL | SSGAC_College | ETC | Rietveld | 2013 | NA | 101069 | 1.00e-5 | 4.92e-3 |
HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-2 | 2.10e-2 |
HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-3 | 7.26e-3 |
HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-4 | 4.07e-3 |
HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-5 | 4.22e-2 |
PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 5.00e-2 | 3.57e-3 |
PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-2 | 2.82e-3 |
PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-3 | 6.55e-5 |
PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-4 | 5.06e-6 |
PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-5 | 1.19e-4 |
SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 5.00e-2 | 2.95e-7 |
SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-2 | 1.13e-5 |
SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-3 | 1.18e-5 |
SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-4 | 9.74e-6 |
SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-5 | 5.61e-6 |
T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 5.00e-2 | 3.31e-2 |
T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-3 | 2.96e-2 |
T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-4 | 4.55e-3 |
T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-5 | 4.89e-4 |
EOC | Epithelial Ovarian Cancer | ETC | Phelan | 2017 | 25509 | 40941 | 5.00e-2 | 2.45e-2 |
AUD | Alcohol Dependency | ETC | Walters | 2018 | 11569 | 34999 | 5.00e-2 | 3.87e-2 |
MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 5.00e-2 | 1.77e-7 |
MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-2 | 1.66e-5 |
MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-3 | 5.05e-5 |
MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-4 | 4.20e-4 |
MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-5 | 1.22e-4 |
SCZ | Schizophrenia | ETC | Pardinas | 2018 | 40675 | 64643 | 1.00e-3 | 2.97e-2 |
SCZ | Schizophrenia | ETC | Pardinas | 2018 | 40675 | 64643 | 1.00e-5 | 4.22e-3 |
CEL | Celiac Disease | ETC | Trynka | 2011 | 12041 | 12228 | 5.00e-2 | 5.00e-3 |
CEL | Celiac Disease | ETC | Trynka | 2011 | 12041 | 12228 | 1.00e-2 | 3.98e-3 |
CEL | Celiac Disease | ETC | Trynka | 2011 | 12041 | 12228 | 1.00e-3 | 1.08e-2 |
Active | Time to most active 10 hours | ETC | Jones | 2019 | NA | 85670 | 1.00e-4 | 9.41e-3 |
Sleep | Sleep duration | ETC | Jones | 2019 | NA | 85449 | 1.00e-4 | 2.69e-2 |
Sleep | Sleep number of episodes | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 1.90e-2 |
Facial attractiveness | Facial attractiveness of females, female raters | ETC | Hu | 2019 | NA | 2062 | 5.00e-2 | 3.59e-2 |
Facial attractiveness | Facial attractiveness of females, male raters | ETC | Hu | 2019 | NA | 2062 | 5.00e-2 | 2.03e-2 |
Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 5.00e-2 | 1.77e-3 |
Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-2 | 6.32e-4 |
Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-3 | 9.59e-5 |
Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-4 | 4.18e-4 |
Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-5 | 1.04e-4 |
Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 5.00e-2 | 2.82e-3 |
Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-2 | 1.36e-3 |
Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-3 | 1.89e-4 |
Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-4 | 2.14e-4 |
Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-5 | 1.49e-4 |
Neuroticism | General factor of neuroticism | ETC | Hill | 2019 | NA | 270059 | 5.00e-2 | 2.03e-2 |
Neuroticism | General factor of neuroticism | ETC | Hill | 2019 | NA | 270059 | 1.00e-2 | 4.14e-2 |
Neuroticism | General factor of neuroticism | ETC | Hill | 2019 | NA | 270059 | 1.00e-3 | 3.23e-2 |
Neuroticism | General factor of neuroticism | ETC | Hill | 2019 | NA | 270059 | 1.00e-4 | 1.72e-2 |
Na/K ratio | Urinary sodium to potassium ratio | ETC | Zanetti | 2019 | NA | 108942 | 5.00e-2 | 1.21e-2 |
Na/K ratio | Urinary sodium to potassium ratio | ETC | Zanetti | 2019 | NA | 108942 | 1.00e-2 | 1.20e-2 |
Na/K ratio | Urinary sodium to potassium ratio | ETC | Zanetti | 2019 | NA | 108942 | 1.00e-3 | 4.23e-2 |
Sleep | Sleep duration | ETC | Dashti | 2019 | NA | 446118 | 1.00e-2 | 7.59e-3 |
Sleep | Sleep duration | ETC | Dashti | 2019 | NA | 446118 | 1.00e-3 | 2.03e-2 |
CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-5 | 2.61e-2 |
MI/CF | Meconium ileus in cystic fibrosis | ETC | Gong | 2019 | 1115 | 5655 | 1.00e-2 | 3.39e-2 |
Chronotype | Chronotype | ETC | Jones | 2019 | NA | 449734 | 1.00e-3 | 2.30e-2 |
Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 5.00e-2 | 2.51e-3 |
Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-2 | 7.90e-5 |
Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-3 | 5.25e-4 |
Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-4 | 3.14e-5 |
Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-5 | 3.36e-3 |
Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 5.00e-2 | 2.82e-2 |
Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-3 | 2.48e-2 |
Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-4 | 7.81e-3 |
Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-5 | 3.00e-3 |
Body fat distribution | Body fat distribution, leg fat ratio, male | ETC | Andersen | 2019 | NA | 116138 | 5.00e-2 | 5.60e-3 |
Body fat distribution | Body fat distribution-trunk-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 5.00e-2 | 4.79e-3 |
Osteoarthritis | Osteoarthritis | ETC | Tachmazidou | 2019 | 77052 | 378169 | 1.00e-3 | 7.26e-3 |
Osteoarthritis | Osteoarthritis hip | ETC | Tachmazidou | 2019 | 15704 | 378169 | 1.00e-4 | 2.87e-2 |
Osteoarthritis | Knee osteoarthritis | ETC | Tachmazidou | 2019 | 24955 | 376169 | 5.00e-2 | 9.60e-3 |
Brain volume | White matter hyperintensity volume | ETC | Traylor | 2019 | NA | 8429 | 5.00e-2 | 4.82e-2 |
Depression | Depressive-symptoms | ETC | Baselmans | 2019 | NA | 1067913 | 5.00e-2 | 4.12e-4 |
Depression | Depressive-symptoms | ETC | Baselmans | 2019 | NA | 1067913 | 1.00e-2 | 1.20e-2 |
Depression | Depressive-symptoms | ETC | Baselmans | 2019 | NA | 1067913 | 1.00e-3 | 2.37e-2 |
Depression | Depressive-symptoms | ETC | Baselmans | 2019 | NA | 1067913 | 1.00e-4 | 3.25e-2 |
Neuroticism | Neuroticism | ETC | Baselmans | 2019 | NA | 523783 | 5.00e-2 | 8.33e-3 |
Neuroticism | Neuroticism | ETC | Baselmans | 2019 | NA | 523783 | 1.00e-3 | 2.23e-2 |
Psoriatic arthritis | Psoriatic arthritis | ETC | Aterido | 2018 | 744 | 1454 | 5.00e-2 | 4.03e-3 |
Psoriatic arthritis | Psoriatic arthritis | ETC | Aterido | 2018 | 744 | 1454 | 1.00e-2 | 1.17e-2 |
Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-3 | 6.17e-3 |
Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-4 | 4.15e-4 |
Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-5 | 1.82e-4 |
Sleep | Sleep duration | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 2.89e-3 |
Physical activity | Physical activity, overall physical activity time | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 2.61e-2 |
Physical activity | Physical activity, moderate intensity activity duration | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 1.22e-3 |
Heart failure | Heart failure | ETC | Aragam | 2018 | 6504 | 387652 | 1.00e-3 | 7.49e-4 |
Subiculum volume | Subiculum volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 4.97e-2 |
Brain volume | Dentate gyrus molecular layer volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 4.64e-2 |
Brain volume | Dentate gyrus granule cell layer volume corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 1.08e-2 |
Hippocampal volume | Hippocampal subfield CA3 volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 3.60e-2 |
Hippocampal volume | Hippocampal subfield CA3 volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 2.95e-2 |
ACR | Urinary albumin to creatinine ratio | ETC | Zanetti | 2019 | NA | 218759 | 5.00e-2 | 1.26e-4 |
ACR | Urinary albumin to creatinine ratio | ETC | Zanetti | 2019 | NA | 218759 | 1.00e-2 | 8.78e-3 |
Na/C | Urinary sodium to creatinine ratio | ETC | Zanetti | 2019 | NA | 218450 | 5.00e-2 | 1.25e-2 |
AUD | Alcohol-Use-Disorder | ETC | Kranzler | 2019 | 34658 | 167346 | 1.00e-3 | 2.27e-2 |
Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 5.00e-2 | 1.10e-5 |
Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-2 | 1.72e-4 |
Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-3 | 1.66e-2 |
Medication use | Medication use (drugs used in diabetes) | ETC | Wu Y | 2019 | 15,272 | 290,641 | 5.00e-2 | 7.30e-3 |
Medication use | Medication use (drugs used in diabetes) | ETC | Wu Y | 2019 | 15,272 | 290,641 | 1.00e-2 | 5.86e-5 |
Medication use | Medication use (drugs used in diabetes) | ETC | Wu Y | 2019 | 15,272 | 290,641 | 1.00e-3 | 4.75e-5 |
Medication use | Medication use (drugs used in diabetes) | ETC | Wu Y | 2019 | 15,272 | 290,641 | 1.00e-4 | 4.00e-3 |
Medication use | Medication use (drugs used in diabetes) | ETC | Wu Y | 2019 | 15,272 | 290,641 | 1.00e-5 | 1.18e-3 |
Medication use | Medication use (vasodilators used in cardiac diseases) | ETC | Wu Y | 2019 | 5,546 | 237,113 | 5.00e-2 | 2.77e-3 |
Medication use | Medication use (antihypertensives) | ETC | Wu Y | 2019 | 6,431 | 145,949 | 5.00e-2 | 3.11e-2 |
Medication use | Medication use (beta blocking agents) | ETC | Wu Y | 2019 | 31,700 | 192,324 | 5.00e-2 | 4.03e-3 |
Medication use | Medication use (diuretics) | ETC | Wu Y | 2019 | 34,453 | 194,633 | 1.00e-2 | 1.06e-3 |
Medication use | Medication use (calcium channel blockers) | ETC | Wu Y | 2019 | 31,904 | 172,474 | 1.00e-2 | 4.80e-3 |
Medication use | Medication use (calcium channel blockers) | ETC | Wu Y | 2019 | 31,904 | 172,474 | 1.00e-5 | 2.51e-2 |
Medication use | Medication use (agents acting on the renin-angiotensin system) | ETC | Wu Y | 2019 | 62,752 | 174,778 | 1.00e-2 | 3.51e-2 |
Medication use | Medication use (agents acting on the renin-angiotensin system) | ETC | Wu Y | 2019 | 62,752 | 174,778 | 1.00e-3 | 3.45e-2 |
Medication use | Medication use (agents acting on the renin-angiotensin system) | ETC | Wu Y | 2019 | 62,752 | 174,778 | 1.00e-4 | 2.37e-2 |
Medication use | Medication use (HMG CoA reductase inhibitors) | ETC | Wu Y | 2019 | 73,475 | 216,910 | 1.00e-2 | 1.31e-2 |
Medication use | Medication use (HMG CoA reductase inhibitors) | ETC | Wu Y | 2019 | 73,475 | 216,910 | 1.00e-5 | 1.78e-2 |
Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-2 | 2.37e-3 |
Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-3 | 2.54e-3 |
Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-4 | 1.14e-4 |
Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-5 | 2.31e-4 |
Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 5.00e-2 | 3.75e-2 |
Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-2 | 1.43e-2 |
Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-3 | 6.03e-3 |
Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-4 | 2.90e-4 |
Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-5 | 3.19e-5 |
Medication use | Medication use (anti-inflammatory and antirheumatic products, non-steroids) | ETC | Wu Y | 2019 | 74,150 | 90,370 | 5.00e-2 | 2.22e-2 |
Medication use | Medication use (anti-inflammatory and antirheumatic products, non-steroids) | ETC | Wu Y | 2019 | 74,150 | 90,370 | 1.00e-2 | 2.78e-2 |
Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-2 | 9.00e-3 |
Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-3 | 3.39e-2 |
Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-4 | 3.00e-3 |
Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-5 | 7.02e-4 |
Medication use | Medication use (opioids) | ETC | Wu Y | 2019 | 22,982 | 55,826 | 5.00e-2 | 2.12e-4 |
Medication use | Medication use (opioids) | ETC | Wu Y | 2019 | 22,982 | 55,826 | 1.00e-4 | 3.65e-3 |
Medication use | Medication use (opioids) | ETC | Wu Y | 2019 | 22,982 | 55,826 | 1.00e-5 | 3.52e-4 |
Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 5.00e-2 | 9.15e-3 |
Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-2 | 1.51e-2 |
Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-3 | 1.48e-5 |
Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-4 | 4.34e-4 |
Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-5 | 1.69e-2 |
Medication use | Medication use (antidepressants) | ETC | Wu Y | 2019 | 33,757 | 270,405 | 1.00e-2 | 4.51e-2 |
Medication use | Medication use (antidepressants) | ETC | Wu Y | 2019 | 33,757 | 270,405 | 1.00e-4 | 4.87e-3 |
Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 5.00e-2 | 4.90e-2 |
Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-2 | 4.00e-3 |
Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-3 | 5.38e-4 |
Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-4 | 2.16e-5 |
Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-5 | 5.61e-6 |
Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 5.00e-2 | 4.25e-6 |
Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-2 | 2.28e-6 |
Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-3 | 1.02e-4 |
Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-4 | 3.33e-7 |
Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-5 | 1.10e-6 |
Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 5.00e-2 | 2.23e-4 |
Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-2 | 2.33e-4 |
Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-3 | 1.03e-4 |
Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-4 | 1.54e-5 |
Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-5 | 9.29e-5 |
Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 5.00e-2 | 1.27e-2 |
Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 1.00e-2 | 1.05e-2 |
Varicose veins | Varicose veins | ETC | Shadrina AS | 2019 | 10,861 | 397,594 | 5.00e-2 | 3.70e-2 |
Varicose veins | Varicose veins | ETC | Shadrina AS | 2019 | 10,861 | 397,594 | 1.00e-2 | 2.69e-2 |
Varicose veins | Varicose veins | ETC | Shadrina AS | 2019 | 10,861 | 397,594 | 1.00e-3 | 2.67e-2 |
Varicose veins | Varicose veins | ETC | Shadrina AS | 2019 | 10,861 | 397,594 | 1.00e-5 | 1.13e-2 |
Glomerular filtration rate | Estimated glomerular filtration rate | ETC | Wuttke M | 2019 | NA | 567,460 | 1.00e-3 | 3.73e-2 |
Glomerular filtration rate | Estimated glomerular filtration rate | ETC | Wuttke M | 2019 | NA | 567,460 | 1.00e-4 | 4.79e-2 |
Blood urea nitrogen levels | Blood urea nitrogen levels | ETC | Wuttke M | 2019 | NA | 243,029 | 1.00e-2 | 4.27e-2 |
Periodontal disease | Periodontal disease related phenotype (PCT6) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 4.49e-2 |
Periodontal disease | Periodontal disease related phenotype (PCT6) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-3 | 3.23e-3 |
Multisite chronic pain | Multisite chronic pain | ETC | Johnston KJA | 2019 | NA | 387,649 | 1.00e-2 | 6.04e-3 |
Multisite chronic pain | Multisite chronic pain | ETC | Johnston KJA | 2019 | NA | 387,649 | 1.00e-3 | 8.16e-4 |
Urinary sodium excretion | Urinary sodium excretion | ETC | Pazoki R | 2019 | NA | 446,237 | 1.00e-2 | 4.56e-2 |
Urinary sodium excretion | Urinary sodium excretion | ETC | Pazoki R | 2019 | NA | 446,237 | 1.00e-3 | 1.95e-2 |
Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 5.00e-2 | 2.98e-3 |
Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 1.00e-2 | 4.29e-4 |
Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 1.00e-3 | 3.67e-5 |
Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 1.00e-4 | 3.01e-4 |
Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 1.00e-5 | 1.90e-3 |
same-sex sexual behaviour | same-sex sexual behaviour Male | ETC | Ganna A | 2019 | NA | 188,825 | 5.00e-2 | 7.76e-3 |
same-sex sexual behaviour | same-sex sexual behaviour Male | ETC | Ganna A | 2019 | NA | 188,825 | 1.00e-2 | 1.38e-2 |
same-sex sexual behaviour | same-sex sexual behaviour Male | ETC | Ganna A | 2019 | NA | 188,825 | 1.00e-3 | 2.70e-3 |
same-sex sexual behaviour | same-sex sexual behaviour Male | ETC | Ganna A | 2019 | NA | 188,825 | 1.00e-4 | 2.22e-2 |
same-sex sexual behaviour | same-sex sexual behaviour Female | ETC | Ganna A | 2019 | NA | 220,170 | 1.00e-4 | 4.37e-2 |
same-sex sexual behaviour | same-sex sexual behaviour | ETC | Ganna A | 2019 | NA | 408,995 | 1.00e-2 | 4.35e-2 |
same-sex sexual behaviour | same-sex sexual behaviour | ETC | Ganna A | 2019 | NA | 408,995 | 1.00e-3 | 2.79e-2 |
Frontal lobe volume | Frontal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 5.00e-2 | 1.64e-2 |
Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Teumer A | 2019 | NA | 547,361 | 5.00e-2 | 4.83e-4 |
Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Teumer A | 2019 | NA | 547,361 | 1.00e-2 | 1.07e-2 |
Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Teumer A | 2019 | NA | 547,361 | 1.00e-3 | 2.71e-2 |
Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 1.00e-2 | 1.74e-3 |
Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 1.00e-3 | 1.73e-3 |
Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 1.00e-4 | 9.54e-3 |
Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 1.00e-5 | 2.79e-4 |
Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 5.00e-2 | 3.16e-4 |
Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-2 | 8.48e-4 |
Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-3 | 6.94e-3 |
Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-4 | 2.56e-3 |
Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-5 | 3.67e-4 |
Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 5.00e-2 | 2.24e-3 |
Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 1.00e-2 | 3.31e-2 |
Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 1.00e-3 | 9.61e-3 |
Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 1.00e-4 | 2.60e-2 |
Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 1.00e-5 | 2.51e-3 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-5 | 3.13e-2 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 697,734 | 1.00e-4 | 6.66e-3 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 316,772 | 1.00e-3 | 2.60e-2 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 316,772 | 1.00e-4 | 1.01e-2 |
Joint damage | Joint damage in rheumatoid arthritis | ETC | Traylor M | 2019 | NA | 2,527 | 1.00e-2 | 3.81e-2 |
Joint damage | Joint damage in rheumatoid arthritis | ETC | Traylor M | 2019 | NA | 2,527 | 1.00e-3 | 4.01e-3 |
Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 5.00e-2 | 4.25e-2 |
Waist to hip ratio | Waist-hip ratio variance | ETC | Wang H | 2019 | NA | 347,134 | 1.00e-2 | 3.66e-2 |
Height | Height variance | ETC | Wang H | 2019 | NA | 347,086 | 1.00e-2 | 1.02e-2 |
Lung function | Lung function (forced vital capacity) variance | ETC | Wang H | 2019 | NA | 317,222 | 5.00e-2 | 1.56e-2 |
Lung function | Lung function (FEV1/FVC) variance | ETC | Wang H | 2019 | NA | 316,614 | 5.00e-2 | 1.47e-3 |
Waist to hip ratio | BMI-adjusted waist-hip ratio variance | ETC | Wang H | 2019 | NA | 346,535 | 5.00e-2 | 1.28e-2 |
Waist to hip ratio | BMI-adjusted waist-hip ratio variance | ETC | Wang H | 2019 | NA | 346,535 | 1.00e-2 | 1.49e-2 |
Waist to hip ratio | BMI-adjusted waist-hip ratio variance | ETC | Wang H | 2019 | NA | 346,535 | 1.00e-3 | 9.05e-3 |
Waist to hip ratio | BMI-adjusted waist-hip ratio variance | ETC | Wang H | 2019 | NA | 346,535 | 1.00e-4 | 5.77e-4 |
Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 5.00e-2 | 9.63e-3 |
Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-2 | 3.06e-3 |
Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-3 | 1.03e-5 |
Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-4 | 4.91e-6 |
Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-5 | 7.12e-5 |
Macular degeneration | Disease progression in age-related macular degeneration (adjusted for baseline) | ETC | Yan Q | 2018 | NA | 2,721 | 1.00e-2 | 4.88e-2 |
Macular degeneration | Disease progression in age-related macular degeneration (adjusted for baseline) | ETC | Yan Q | 2018 | NA | 2,721 | 1.00e-3 | 5.82e-3 |
Heavy menstrual bleeding | Heavy menstrual bleeding | ETC | Gallagher CS | 2019 | 9,813 | 210,946 | 5.00e-2 | 1.06e-2 |
Cytokine network | Cytokine network levels (multivariate analysis) | ETC | Nath AP | 2019 | NA | 9,263 | 5.00e-2 | 4.06e-2 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 5.00e-2 | 4.07e-2 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-2 | 1.60e-3 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-3 | 4.17e-4 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-4 | 7.24e-6 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-5 | 1.87e-6 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (ANCA negative) | ETC | Lyons PA | 2019 | 352 | 6,688 | 1.00e-2 | 1.20e-2 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (ANCA negative) | ETC | Lyons PA | 2019 | 352 | 6,688 | 1.00e-3 | 7.15e-3 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 5.00e-2 | 1.37e-2 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 1.00e-2 | 2.79e-2 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 1.00e-3 | 6.05e-4 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 1.00e-4 | 3.63e-7 |
BMI by age | BMI at 6 weeks old | ETC | Helgeland O | 2019 | NA | 6,450 | 1.00e-2 | 1.38e-2 |
BMI by age | BMI at 6 months old | ETC | Helgeland O | 2019 | NA | 8,017 | 5.00e-2 | 2.71e-3 |
BMI by age | BMI at 5 years old | ETC | Helgeland O | 2019 | NA | 4,245 | 5.00e-2 | 4.15e-2 |
BMI by age | BMI at 7 years old | ETC | Helgeland O | 2019 | NA | 4,629 | 1.00e-3 | 1.17e-2 |
PD | Parkinson's disease in GBA mutation carriers | ETC | Blauwendraat C | 2020 | 1,588 | 7,584 | 5.00e-2 | 3.16e-2 |
Left ventricular | Left ventricular mass to end-diastolic volume ratio | ETC | Aung N | 2019 | NA | 16,884 | 5.00e-2 | 3.33e-2 |
Left ventricular | Left ventricular mass to end-diastolic volume ratio | ETC | Aung N | 2019 | NA | 16,884 | 1.00e-4 | 1.75e-2 |
Left ventricular | Left ventricular mass to end-diastolic volume ratio | ETC | Aung N | 2019 | NA | 16,884 | 1.00e-5 | 1.50e-3 |
Left ventricular | Left ventricular end-systolic volume | ETC | Aung N | 2019 | NA | 16,920 | 1.00e-4 | 1.98e-2 |
Left ventricular | Left ventricular end-diastolic volume | ETC | Aung N | 2019 | NA | 16,920 | 5.00e-2 | 1.07e-2 |
Left ventricular | Left ventricular end-diastolic volume | ETC | Aung N | 2019 | NA | 16,920 | 1.00e-2 | 3.59e-2 |
Optic disc area | Optic disc area | ETC | Bonnemaijer PWM | 2019 | NA | 24,509 | 5.00e-2 | 2.68e-2 |
Optic disc area | Optic disc area | ETC | Bonnemaijer PWM | 2019 | NA | 24,509 | 1.00e-2 | 3.40e-2 |
Refractive error | Refractive error (age-at-onset of spectacle wearing-inferred) | ETC | Ghorbani Mojarrad N | 2020 | NA | 287,448 | 1.00e-2 | 3.37e-3 |
Refractive error | Refractive error (age-at-onset of spectacle wearing-inferred) | ETC | Ghorbani Mojarrad N | 2020 | NA | 287,448 | 1.00e-3 | 2.45e-2 |
Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-2 | 1.42e-3 |
Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-3 | 1.90e-4 |
Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-4 | 1.51e-4 |
Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-5 | 3.46e-2 |
Household income | Household income | ETC | Hill WD | 2019 | NA | 286,301 | 5.00e-2 | 3.13e-2 |
Household income | Household income | ETC | Hill WD | 2019 | NA | 286,301 | 1.00e-4 | 9.21e-4 |
Household income | Household income | ETC | Hill WD | 2019 | NA | 286,301 | 1.00e-5 | 3.90e-4 |
Household income (MTAG) | Household income (MTAG) | ETC | Hill WD | 2019 | NA | 505,541 | 1.00e-3 | 3.73e-2 |
Household income (MTAG) | Household income (MTAG) | ETC | Hill WD | 2019 | NA | 505,541 | 1.00e-4 | 1.94e-2 |
Household income (MTAG) | Household income (MTAG) | ETC | Hill WD | 2019 | NA | 505,541 | 1.00e-5 | 1.26e-3 |
MHC class I | MHC class I polypeptide-related sequence A levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 1.37e-3 |
MHC class I | MHC class I polypeptide-related sequence A levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 3.38e-2 |
Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Casanova F | 2019 | NA | 437,027 | 1.00e-2 | 2.57e-4 |
Steroid sensitive nephrotic syndrome | Childhood steroid-sensitive nephrotic syndrome | ETC | Debiec H | 2018 | 132 | 2,000 | 1.00e-2 | 1.36e-3 |
Steroid sensitive nephrotic syndrome | Childhood steroid-sensitive nephrotic syndrome | ETC | Debiec H | 2018 | 132 | 2,000 | 1.00e-3 | 2.19e-4 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 5.00e-2 | 1.17e-2 |
Snoring | Snoring main | ETC | Campos AI | 2020 | 152,302 | 256,015 | 5.00e-2 | 3.64e-3 |
Snoring | Snoring adjusted BMI | ETC | Campos AI | 2020 | 151,836 | 255,230 | 5.00e-2 | 2.72e-2 |
Snoring | Snoring male | ETC | Campos AI | 2020 | 90,806 | 99,165 | 5.00e-2 | 4.00e-2 |
* If the number of cases is 0/NA, it means the phenotype is a continuous data type and the number of controls is the total number of samples.